RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who
have recurrent ovarian, fallopian tube, or primary peritoneal cancer.
OBJECTIVES: I. Determine the response rate and time to treatment failure in patients with
recurrent ovarian epithelial, fallopian tube, or primary peritoneal carcinoma treated with
oral capecitabine. II. Determine the tolerability and safety of this regimen in these
OUTLINE: Patients receive oral capecitabine twice daily for 14 days. Treatment continues
every 3 weeks in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 14-35 patients will be accrued for this study.
DISEASE CHARACTERISTICS: Histologically confirmed recurrent ovarian epithelial carcinoma,
fallopian tube cancer, or primary peritoneal cancer previously treated with at least one
cisplatin based chemotherapy regimen Prior repeat treatment with a taxane and/or platinum
agent allowed Prior repeat treatment with other chemotherapy agent allowed once Recurrent
disease defined as: At least one site of measurable disease by radiograph and/or a rise of
CA-125 over a minimum of 3 samples to a level of at least 50% of upper limit of normal
PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70-100% Life
expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,000/mm3
Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 2.0 times upper limit of
normal (ULN) SGOT less than 2.0 times ULN Alkaline phosphatase less than 2.0 times ULN
Renal: Creatinine no greater than 1.5 mg/dL Other: Must be able to take oral medication
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics No prior fluorouracil based chemotherapy Endocrine therapy: Not specified
Radiotherapy: Not specified Surgery: Not specified